SUMMARY Treatment with an anticoagulant (AC) or acetylsalicylic acid (ASA), chosen at random, was given to 241 patients with symptoms of carotid transient attacks of ischemia, some of whom recovered completely within 24 hours (TIA) while the others had slight residual symptoms (TIA-IR).
dipyridamol) were compared. In the former study no significant difference was observed. In the latter study all the patients received AC treatment initial 2 months after TIAs, before randomization was performed. Dur ing a 2-year follow-up the incidence of cerebral ische mic events was significantly lower in the AC group of patients. For these, however, the incidence of hemor rhagic complications was higher.
The aim of the present study was to compare the outcome of treatment with AC and ASA in patients with carotid TIA with or without complete recovery (TIA-IR). Primary end-points were cerebral infarc tion, recurrent TIAs, TIA-IR and death. Furthermore, the incidence of cerebral haemorrhage and various side-reactions was monitored. Care was taken also to register certain base-line variables, such as cardiovas cular symptoms and to monitor compliance by regular interviews and pharmacologic tests.
Patients and Methods
The series for this study consisted of 241 patients, 155 of them men and 86 women, aged 28-77 years (mean age 60.0 years). They had been under observa tion for transient ischemic attacks, with or without complete recovery, at either the South Stockholm Hos pital or at Huddinge Hospital between November 1976 and September 1980. Only patients with carotid symp toms (amaurosis fugax, hemiparesis, hemi-hypesthesia) or homonymous visual defects were accepted. Pa tients with only monoparesis or monohypesthesia were included only if these symptoms were combined with dysphasia or central facial paresis. A diagnosis of tran sient ischemic attack with complete recovery (TIA), was made for 104 of the patients, and of such attacks but with incomplete recovery (TIA-IR) in 137; the criteria for the latter classification was that at least mild symptoms remained after 24 hours. Patients that were either unable or unwilling to cooperate or that were of advanced age, and those with current gastritis, peptic ulcer, or severe systemic diseases, including malig-nant tumors and collagenosis, were excluded, as also were patients with disorders for which the preferential treatment was administration of one of the two types of agents in question, -e.g. patients with atrial fibrilla tion, deep venous thrombosis, rheumatic diseases or other disorders accompanied by chronic pain. Nine otherwise healthy and young patients underwent carot id endarterectomy because of relevant fairly tight ste nosis, and they were not included in the study. In no case the interval between the signs of TIA or TIA-IR and the introduction of the treatment exceeded 14 days. Within this period lumbar puncture, and either computed tomography or radionuclide brain scanning, with measurement of the cerebral flow, were per formed. Aortic certical angiography was only per formed in those 18 patients in whom surgery was con sidered, but the above mentioned criteria were not fulfilled. Electrocardiography, cardiac radiography, routine hematologic examination, including a total platelet count, and a routine urine examination were also carried out. On entry into the study note was taken of any history of earlier cerebrovascular symptoms (table 3) . The Simplastin A test values for these 2 patients were 25 och 31% and for the other 2 patients 11 and 8%. The last of these patients suffered of a lateral medullary infarction, with no sign of cerebral hemorrhage, but there was concurrent hematemesis. In the ASA group, too, cerebral infarction was recorded in 4 patients, 2 of them within the first 4 months and the others after 12 and 19 months (table 3). The number of patients who had TIAs and TIA-IR was comparable in the two treat ment groups. Of the 32 AC patients experiencing 3= 2 TIAs within 14 days before randomization 12 (38%) had a cerebral infarction, TIA or TIA-IR. The corre sponding figure for the ASA group was 6 patients out of 24 (25%). Furthermore, the incidence of TIA and TIA-IR was similar for patients with history of CVS- symptoms, ^ 14 days before randomization and in those with carotid bruits, irrespective of treatment with AC (6%) and ASA (5%). In the AC group there were 3 deaths, 1 from cerebral and 2 from myocardial infarction. In the ASA group there were also 3 deaths, one each from cerebral hem orrhage, myocardial infarction and pulmonary infarc tion. Discontinuation of the treatment owing to severe hemorrhage was decided on in 8 patients of the AC group and in 4 of the ASA group, including the pa tients with cerebral hemorrhage (table 4). The drug therapy for 5 patients of the ASA group was withdrawn because of gastrointestinal disorders, usually constipa tion, and in 3 others owing to skin allergy or pruritus. Two patients developed atrial fibrillation and were transferred to AC therapy. Three patients in the AC group and 5 in the ASA group were unable or unwill ing to cooperate in the treatment.
The total number of patients in whom cerebral ische mic events were recorded was 33 (table 5) . Compared with the rest of the patients these 33 patients had a significantly higher incidence of the following 3 base line variables: > 2 TIAs within 14 days of randomiza tion (p < 0.001), a previous history of cerebrovascular symptoms (p < 0.001) and occurrence of carotid bruits (p < 0.01). Angina pectoris and intermittent claudica tion tended to be more frequent among the patients with new ischemic symptoms, but the difference was not statistically significant.
Discussion
In this study on 241 patients with carotid TIA and TIA-IR followed for 20 months, on average, there was no statistically significant difference between the 2 groups receiving anticoagulant and acetylsalicylic acid 1, 3, 15, 33 months.  tAfter < 1, 4, 12, 19 therapy, as regards the incidence of cerebral infarction: this was recorded in 3.5 and 3.1% respectively. Nor was there any statistically significant, difference in the occurrence of TIA in the'ACand ASA groups (9.7 and 7.1%) or TIA-IR (2.6 and 1%). It is notable that among the 56 patients recording more than > 2 TIAs there was no difference between the treatment groups as regards the incidence of cerebral ischemic events. The results are consistent with those reported by Buren 8 and Olsson 9 in which AC treatment was com pared to anti-platelet therapy while the dose of ASA was the same in these 3 studies, in those of Buren and Olsson this drug was used in combination with dipyridamol. In Olsson's study the ASA treatment was pre ceded by a 2-month period of AC. The percentages thrombotest values lying within the acceptable thera peutic range was 78%. The compliance of AC as tested in a sample of 63 patients was acceptable at the figure correspondable to that given in the Olsson study (85%). The ASA compliance tested in a 62/127 group of patients was acceptable in the present study.
The incidences of severe complications in the form of hemorrhage in these 3 Swedish studies, are compa rable, 7.0, 6.7 8 and 8.8%. 9 During antiplatelet therapy the frequencies of hemorrhage were 3.2, 4.5 8 and 4.5%. 9 The fact that the less severe gastrointestinal side reactions led to withdrawal of the ASA therapy will be due more to the patients attitude to the ASA therapy than to the severity of the drug reaction. Alto gether the results of the present study indicate that ASA is just as effective as AC therapy and leads to less severe complication in the form of hemorrhage.
One question that now arises is whether the fre quency of cerebral ischemic event in patients treated with either AC or ASA differs from the spontaneous occurrence. The outcome for untreated TIA patients in 12 studies have been reviewed by Brust. 4 In the Cana dian 7 and the Field 6 studies a further 139 and 90 control patients, respectively, were followed. For the total of 665 control patients included in these 3 papers, 4 ' 6 -7 the incidence of stroke during 30 months (range 6-60 months) was 18%. The fact that this figure greatly exceeds the present ones of 3.5 and 3.1% over 20 months for the AC and ASA groups, respectively, does not afford proof of the beneficial effect of the treat ment, since there may be considerable differences in the patient materials. Baseline findings presented in the Field study enable some comparison to be made with the present study. In the American trial of aspirin after carotid TIAs cerebral infarction was recorded within 24 months in 9 out of 88 of the patients on aspirin (10.2%) and in 14 out of 90 of the patients given placebo (15.5%). Thus, in both groups the inci dence of cerebral infarction was higher than it was among the patients of our AC and ASA groups (6.1 and 4.7%, respectively). A comparison of some base line findings and risk factors among patients having a cerebral ischemic event during treatment and those with a "favorable" outcome is presented in table 5. The fact that recurrent TIAs, a previous history of CVS symptoms and carotid bruits were significantly more common among the former group indicates that these were the most significant risk factors. For this reason in the interpretation of the results of prophylactic treat ment for CVS a careful evaluation of the risk profile for the patient group is of prime importance. The dif-AC OR ASA TREATMENT AFTER TIAJGdrde et al 681 ference in the outcome in the Field and the present series is thus probable ascribable to the considerably higher proportion of patients with recurrent TIAs be fore randomization in the Field study (116/178, or 65% against 23%). The results of both these studies, as also others, [7] [8] [9] suggest that anti-aggregation therapy should be given to the patient with TIA unless there is surgical accessible stenosis or a cardiac source of embolies, when AC therapy should be considered. Although the present study does not include sufficient number of patients required for statistically evaluation of differ ence between two treatment forms in TIA and TIA-IR, the lack of difference between the two treatment groups indicated that in future studies with ASA this treatment could be instituted in the early phase of a study without foregoing AC treatment.
